Efficient clinical trials in Japan: Bridging studies versus participation in global clinical trials

Mari Shirotani, Toshio Suwa, Tatsuo Kurokawa, Koji Chiba

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The required number of Japanese subjects was compared between the Bridging (BG) filing strategy described in ICH-E5 for drugs approved from 1998 to 2012, in which foreign phase 3 results were used together with a BG study conducted to confirm optimum Japanese dose, and global clinical trial (GCT) strategies in which the number was simulated from the foreign phase 3 studies. The simulated number from the GCT strategy was smaller than that of the BG, suggesting that the GCT strategy could be expected to reduce Japanese clinical trial costs. However, two exceptions were found, namely for preventive drugs and drugs for children, because of the large scales of foreign phase 3 studies.

Original languageEnglish
Pages (from-to)438-445
Number of pages8
JournalJournal of Clinical Pharmacology
Volume54
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Japan
Clinical Trials
Pharmaceutical Preparations
Costs and Cost Analysis

Keywords

  • bridging study
  • global clinical trial
  • regulatory science
  • sample size

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Efficient clinical trials in Japan : Bridging studies versus participation in global clinical trials. / Shirotani, Mari; Suwa, Toshio; Kurokawa, Tatsuo; Chiba, Koji.

In: Journal of Clinical Pharmacology, Vol. 54, No. 4, 2014, p. 438-445.

Research output: Contribution to journalArticle

Shirotani, Mari ; Suwa, Toshio ; Kurokawa, Tatsuo ; Chiba, Koji. / Efficient clinical trials in Japan : Bridging studies versus participation in global clinical trials. In: Journal of Clinical Pharmacology. 2014 ; Vol. 54, No. 4. pp. 438-445.
@article{31d6c7e8a1184ba18a2aab43619674e6,
title = "Efficient clinical trials in Japan: Bridging studies versus participation in global clinical trials",
abstract = "The required number of Japanese subjects was compared between the Bridging (BG) filing strategy described in ICH-E5 for drugs approved from 1998 to 2012, in which foreign phase 3 results were used together with a BG study conducted to confirm optimum Japanese dose, and global clinical trial (GCT) strategies in which the number was simulated from the foreign phase 3 studies. The simulated number from the GCT strategy was smaller than that of the BG, suggesting that the GCT strategy could be expected to reduce Japanese clinical trial costs. However, two exceptions were found, namely for preventive drugs and drugs for children, because of the large scales of foreign phase 3 studies.",
keywords = "bridging study, global clinical trial, regulatory science, sample size",
author = "Mari Shirotani and Toshio Suwa and Tatsuo Kurokawa and Koji Chiba",
year = "2014",
doi = "10.1002/jcph.216",
language = "English",
volume = "54",
pages = "438--445",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Efficient clinical trials in Japan

T2 - Bridging studies versus participation in global clinical trials

AU - Shirotani, Mari

AU - Suwa, Toshio

AU - Kurokawa, Tatsuo

AU - Chiba, Koji

PY - 2014

Y1 - 2014

N2 - The required number of Japanese subjects was compared between the Bridging (BG) filing strategy described in ICH-E5 for drugs approved from 1998 to 2012, in which foreign phase 3 results were used together with a BG study conducted to confirm optimum Japanese dose, and global clinical trial (GCT) strategies in which the number was simulated from the foreign phase 3 studies. The simulated number from the GCT strategy was smaller than that of the BG, suggesting that the GCT strategy could be expected to reduce Japanese clinical trial costs. However, two exceptions were found, namely for preventive drugs and drugs for children, because of the large scales of foreign phase 3 studies.

AB - The required number of Japanese subjects was compared between the Bridging (BG) filing strategy described in ICH-E5 for drugs approved from 1998 to 2012, in which foreign phase 3 results were used together with a BG study conducted to confirm optimum Japanese dose, and global clinical trial (GCT) strategies in which the number was simulated from the foreign phase 3 studies. The simulated number from the GCT strategy was smaller than that of the BG, suggesting that the GCT strategy could be expected to reduce Japanese clinical trial costs. However, two exceptions were found, namely for preventive drugs and drugs for children, because of the large scales of foreign phase 3 studies.

KW - bridging study

KW - global clinical trial

KW - regulatory science

KW - sample size

UR - http://www.scopus.com/inward/record.url?scp=84898639581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898639581&partnerID=8YFLogxK

U2 - 10.1002/jcph.216

DO - 10.1002/jcph.216

M3 - Article

C2 - 24165947

AN - SCOPUS:84898639581

VL - 54

SP - 438

EP - 445

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 4

ER -